Latest News
Novartis receives positive CHMP opinion for Itvisma in spinal muscular atrophy
24 April 2026 - Swiss pharmaceutical company Novartis AG (SIX:NOVN) (NYSE:NVS) announced on Friday that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending market...
Servier completes Day One Biopharmaceuticals acquisition
24 April 2026 - French pharmaceutical company Servier announced on Thursday the successful completion of its tender offer to acquire all of the issued and outstanding shares of common stock of Day One Biopharmaceuticals Inc (Nasdaq:DAWN), a US biopha...
Cipla's AB-rated Ventolin HFA generic receives US FDA approval
24 April 2026 - Indian pharmaceutical company Cipla Limited (BSE:500087) (NSE:CIPLA-EQ) and its US subsidiary Cipla USA Inc announced on Thursday that the US Food and Drug Administration (FDA) has given final approval for the Abbreviated New Drug App...
Apotex and Cumberland Pharmaceuticals to integrate their US branded businesses
24 April 2026 - Canadian pharmaceutical company Apotex Inc and Cumberland Pharmaceuticals Inc, a US-based specialty pharmaceutical company, announced on Thursday that they have entered into a strategic transaction to integrate Cumberland's US br...
Orion Pharma launches Phase 1b/2 TEADCO trial of ODM-212 in advanced solid tumours
23 April 2026 - Finnish pharmaceutical company Orion Corporation (Orion Pharma) (HEL:ORNBV) said on Thursday that it has initiated the TEADCO Phase 1b/2 basket trial evaluating ODM-212, an oral pan-TEAD inhibitor, in combination with standard-of-care...